SUSMED has announced that it has initiated a joint research project with the Cancer Institute Hospital of JFCR to investigate the actual status of immune-related adverse events (irAEs) requiring treatment in patients treated with immune checkpoint inhibitors (ICIs).The Cancer Institute Hospital of JFCR has abundant experience and broad knowledge in this field, and by utilizing our expertise in AI analysis and verification of medical big data, this joint research will build a database of irAEs cases, consolidate the collected data, and analyze trends with the aim of discovering actual conditions and predictive factors of irAEs occurrence.